Serum pentosidine levels are positively associated with the presence of vertebral fractures in postmenopausal women with type 2 diabetes.

CONTEXT Although type 2 diabetic patients are at increased risk of fractures, bone mineral density (BMD) may not be useful for assessing the risk. Recent studies have reported that increased bone content of pentosidine (PEN) is associated with its plasma concentration and bone fragility. OBJECTIVE AND METHODS To examine the association between serum PEN levels and vertebral fractures (VFs) in Japanese type 2 diabetic patients (77 males older than 50 yr and 76 postmenopausal females), we compared parameters including BMD, PEN, serum bone-specific alkaline phosphatase, and urinary levels of N-telopeptide between those with and without VFs. RESULTS Comparison of diabetic subjects with and without VFs revealed no significant differences in BMD values or bone metabolic markers in either gender. In contrast, PEN levels in women with VFs were significantly higher than in those without VFs (0.0440+/-0.0136 vs. 0.0321+/-0.0118 microg/ml; P<0.001). Multivariate logistic regression analysis adjusted for age, height, weight, hemoglobin A1c, estimated glomerular filtration rate, the presence of diabetic complications, histories of taking insulin or pioglitazone, risk factors for osteoporosis, and lumbar BMD identified PEN levels as a factor associated with the presence of VFs in postmenopausal diabetic women independent of BMD, risk factors for osteoporosis, diabetic status, and renal function (odds ratio 2.50, 95% confidential interval 1.09-5.73 per sd increase; P=0.0302). CONCLUSION PEN levels, but not BMD, may be useful for assessing the risk of prevalent VFs in postmenopausal diabetic women and may reflect bone quality in this group.

[1]  S. Yano,et al.  The combination of high glucose and advanced glycation end-products (AGEs) inhibits the mineralization of osteoblastic MC3T3-E1 cells through glucose-induced increase in the receptor for AGEs. , 2007, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[2]  T. Sugimoto,et al.  Bone Mineral Density Is not Sensitive Enough to Assess the Risk of Vertebral Fractures in Type 2 Diabetic Women , 2007, Calcified Tissue International.

[3]  M. Bouxsein,et al.  Contribution of the advanced glycation end product pentosidine and of maturation of type I collagen to compressive biomechanical properties of human lumbar vertebrae. , 2006, Bone.

[4]  M. Saito,et al.  Degree of Mineralization-related Collagen Crosslinking in the Femoral Neck Cancellous Bone in Cases of Hip Fracture and Controls , 2006, Calcified Tissue International.

[5]  S. Cummings,et al.  Thiazolidinedione use and bone loss in older diabetic adults. , 2006, The Journal of clinical endocrinology and metabolism.

[6]  M. Saito,et al.  Role of collagen enzymatic and glycation induced cross-links as a determinant of bone quality in spontaneously diabetic WBN/Kob rats , 2006, Osteoporosis International.

[7]  M. Saito,et al.  Reductions in degree of mineralization and enzymatic collagen cross-links and increases in glycation-induced pentosidine in the femoral neck cortex in cases of femoral neck fracture , 2006, Osteoporosis International.

[8]  S. Mohan,et al.  Serum Levels of Insulin-Like Growth Factor (IGF); IGF-Binding Proteins-3, -4, and -5; and Their Relationships to Bone Mineral Density and the Risk of Vertebral Fractures in Postmenopausal Women , 2006, Calcified Tissue International.

[9]  T. Keaveny,et al.  Trabecular microfracture and the influence of pyridinium and non-enzymatic glycation-mediated collagen cross-links. , 2005, Bone.

[10]  P. Odetti,et al.  Advanced Glycation End Products and Bone Loss during Aging , 2005, Annals of the New York Academy of Sciences.

[11]  P. Vestergaard,et al.  Relative fracture risk in patients with diabetes mellitus, and the impact of insulin and oral antidiabetic medication on relative fracture risk , 2005, Diabetologia.

[12]  M. Barbagallo,et al.  Collagen overglycosylation: a biochemical feature that may contribute to bone quality. , 2005, Biochemical and biophysical research communications.

[13]  M. Plebani,et al.  Pentosidine plasma levels and relation with metabolic control in diabetic patients. , 2005, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[14]  Y. Aso,et al.  High serum pentosidine concentrations are associated with increased arterial stiffness and thickness in patients with type 2 diabetes. , 2005, Metabolism: clinical and experimental.

[15]  P. Delmas,et al.  The role of collagen in bone strength , 2005, Osteoporosis International.

[16]  S. Kamohara,et al.  Oxidative DNA damage (8-hydroxydeoxyguanosine) and body iron status: a study on 2507 healthy people. , 2003, Free radical biology & medicine.

[17]  M. Fukunaga,et al.  Fracture Prediction From Bone Mineral Density in Japanese Men and Women , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[18]  C. M. Agrawal,et al.  Age-related changes in the collagen network and toughness of bone. , 2002, Bone.

[19]  A. Hofman,et al.  The Incidence of Vertebral Fractures in Men and Women: The Rotterdam Study , 2002, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[20]  Tsutomu Sanaka,et al.  Plasma Pentosidine Levels Measured by a Newly Developed Method Using ELISA in Patients with Chronic Renal Failure , 2002, Nephron.

[21]  J. D. Luna,et al.  Bone mineral density at time of clinical diagnosis of adult-onset type 1 diabetes mellitus. , 2001, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[22]  R. Cumming,et al.  Diabetes and risk of fracture: The Blue Mountains Eye Study. , 2001, Diabetes care.

[23]  A. Folsom,et al.  Type 1 and type 2 diabetes and incident hip fractures in postmenopausal women. , 2001, Diabetes care.

[24]  A. Barden,et al.  Advanced Glycation End Products: A Review , 2013 .

[25]  S. Cummings,et al.  Older women with diabetes have an increased risk of fracture: a prospective study. , 2001, The Journal of clinical endocrinology and metabolism.

[26]  J. Lutterman,et al.  Osteopenia in insulin-dependent diabetes mellitus; prevalence and aspects of pathophysiology , 2000, Journal of endocrinological investigation.

[27]  F. Escobar-Jiménez,et al.  Intensive Insulin Therapy and Bone Mineral Density in Type 1 Diabetes Mellitus: A Prospective Study , 2000, Osteoporosis International.

[28]  T. Rönnemaa,et al.  Bone mineral density in patients with type 1 and type 2 diabetes. , 1999, Diabetes care.

[29]  L. Forsén,et al.  Diabetes mellitus and the incidence of hip fracture: results from the Nord-Trøndelag Health Survey , 1999, Diabetologia.

[30]  S. Genuth,et al.  Skin collagen glycation, glycoxidation, and crosslinking are lower in subjects with long-term intensive versus conventional therapy of type 1 diabetes: relevance of glycated collagen products versus HbA1c as markers of diabetic complications. DCCT Skin Collagen Ancillary Study Group. Diabetes Contro , 1999, Diabetes.

[31]  T. Miyata,et al.  Plasma levels of pentosidine in diabetic patients: an advanced glycation end product. , 1998, Journal of the American Society of Nephrology : JASN.

[32]  C van Ypersele de Strihou,et al.  Accumulation of albumin-linked and free-form pentosidine in the circulation of uremic patients with end-stage renal failure: renal implications in the pathophysiology of pentosidine. , 1996, Journal of the American Society of Nephrology : JASN.

[33]  M. Brownlee,et al.  Advanced protein glycosylation in diabetes and aging. , 1995, Annual review of medicine.

[34]  A. McElduff,et al.  Diabetes Control and Complications Trial , 1993 .

[35]  M. Nevitt,et al.  Vertebral fracture assessment using a semiquantitative technique , 1993, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[36]  V. Monnier,et al.  Effects of kidney or kidney-pancreas transplantation on plasma pentosidine. , 1993, Kidney international.

[37]  J. Baynes,et al.  Formation of pentosidine during nonenzymatic browning of proteins by glucose. Identification of glucose and other carbohydrates as possible precursors of pentosidine in vivo. , 1991, The Journal of biological chemistry.

[38]  V. Monnier,et al.  Structure elucidation of a senescence cross-link from human extracellular matrix. Implication of pentoses in the aging process. , 1989, The Journal of biological chemistry.

[39]  A. Cerami,et al.  Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. , 1988, The New England journal of medicine.